Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337386 | 0.86 | KDM4E (0.42) | CA1CA2 | |
| SCHEMBL31337195 | 0.78 | KCNQ3 (0.45) | CA1CA2LCKPSMB8GPR119 | |
| SCHEMBL6800712 | 0.73 | CA1 (0.46) | CA1CA2LCKPSMB8 | |
| SCHEMBL24256392 | 0.73 | HTR3A (0.41) | HRH4 | |
| SCHEMBL3680676 | 0.72 | CA1 (0.44) | CA1CA2LCKPSMB8 | |
| SCHEMBL1519841 | 0.72 | CA1 (0.44) | CA1CA2LCKPSMB8 | |
| SCHEMBL31337188 | 0.71 | CA1 (0.50) | CA1CA2LCKPSMB8 | |
| SCHEMBL11392793 | 0.70 | CA1 (0.43) | CA1CA2LCKPSMB8 | |
| SCHEMBL4873003 | 0.70 | KMT2A (0.53) | CA1CA2LCKPSMB8 | |
| SCHEMBL24255878 | 0.69 | HRH4 (0.42) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4377298-A1 | PROTEIN SECRETION INHIBITORS | Gate Bioscience, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117999256-A | Protein secretion inhibitor | 分子门生物科技公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CA1 4430/4885CA2 3723/4885LCK 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.